Latest

BioNTech and Pfizer Reveal New Data – No Safety Concerns With BNT162 – Stock Under Pressure

Yesterday, some investors on NASDAQ took profits on BioNTech shares. The minus on the closing price basis of 6.6 percent to 86.86 dollars, intraday 85.05 dollars were reached, at first glance it seems violent. But two factors played a role here. On the one hand the unsuccessful attempt to attack technical chart obstacles at 96.09 / 97.82 dollars, on the other hand the clear upward movement of the last few weeks, started at 54.10 dollars, which offered the opportunity to take ample profits. In the coming weeks, the BioNTech share will remain news-driven with a focus on the Mainz-based vaccine project against the pathogen of the corona pandemic, which is on the home straight.

There was also news from BioNTech and Pfizer on Thursday night. On the one hand: preliminary, peer-reviewed data from the phase 1 part of the US study on the COVID-19 vaccine candidate BNT162b2, which is now in phase 3, has been published online in the New England Journal of Medicine (NEJM), according to BioNTech. 37,000 test subjects have now been vaccinated. In phase 1, BNT162b2 produced strong immunogenicity in younger and older subjects. “In addition, the administration of BNT162b2 was well tolerated in all population groups, with less than 20 percent of the participants developing mild to moderate fever,” said BioNTech. Especially after the recent stop of clinical trials for other vaccine candidates, among others at Johnson & Johnson, the stockbrokers are nervous about possible side effects.

With BioNTech’s BNT162 program, these problems do not appear to be as severe as with some competitor projects. Side effects are not uncommon with vaccines and the side effects of BNT162b2 that occurred in the phase 3 clinical trial are in line with expectations derived from previous studies. BioNTech CEO Ugur Sahin reassures us in an interview that the study does not have to be stopped because of safety concerns. You can also see yourself on schedule for the study. Data from the ongoing clinical trial should be available later this month.

BioNTech and Pfizer would be on the way to being one of the first companies with a vaccine against the SARS-CoV-2 virus that could be approved, if not the first developer duo. Yesterday’s price gain meanwhile does not break the upward trend of the BioNTech share, even if the first small supports were broken. Other strong supports are in the vicinity – measured by the typical volatility of biotech stocks. The zone between $ 79.38 / $ 80.26 and $ 80.70 / 81.56 should be mentioned in particular. A first, smaller support area already extends around the 85 mark, which was tested yesterday and held.

Related Articles

Back to top button